II. Medications: Hormone Analogs
- Background
- Naturally occurring Hormones or their derivatives
-
Corticosteroids (lymphoid malignancy)
- Short-acting (e.g. Hydrocortisone)
- Intermediate-acting (e.g. Prednisone, Methylprednisolone)
- Long-acting (e.g. Dexamethasone)
-
Somatostatin Analogs (GI neuroendocrine tumors, Carcinoid Syndrome, Merkel Cell carcinoma)
- Octreotide (Sandostatin)
- Lanreotide (Somatuline)
-
Progestins
- Megestrol acetate
- Medroxyprogesterone acetate
- Conjugates (novel, hormonal agents conjugated to a cytotoxic agent)
- Estramustine (EmCyt)
- Estrogen conjugated to an alkylkating agent
- Selective accumulation of alkylating cytotoxic effects in Estrogen receptor positive tumor cells
- Used in Prostate Cancer
- Estramustine (EmCyt)
- Other Uncommonly used (or historically used) hormonal Chemotherapy agents
- Androgens (Historical use in Breast Cancer)
- Fluoxymesterone
- Danazol
- Estrogens (Uncommon use in Prostate Cancer)
- Diethylstilbesterol
- Androgens (Historical use in Breast Cancer)
III. Medications: Hormone Synthesis Inhibitors
- Gonadotropin-Releasing Hormone Agonists (Breast Cancer, Prostate Cancer)
- Gonadotropin-Releasing Hormone Antagonists (Prostate Cancer)
- Androgen Synthesis Inhibitor (Prostate Cancer)
-
Aromatase Inhibitors (Breast Cancer)
- Letrozole (Femara, reversible)
- Anastrozole (Arimidex, reversible)
- Exemestane (Aromasin, irreversible)
- Aminoglutethimide (Cytadren)
IV. Medications: Hormone Receptor Inhibitors
- Selective Estrogen Receptor Modulators (SERMs, Breast Cancer)
- Antiandrogens - Non-Steroidal Testosterone Receptor Antagonists - First Generation (Prostate Cancer)
- Antiandrogens - Non-Steroidal Testosterone Receptor Antagonists - Second Generation (Prostate Cancer)